https://www.optimumcomms.com/wp-content/uploads/2023/08/Astraveus.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-15 08:33:112025-04-15 08:33:11Astraveus Strengthens Leadership Team and Board
https://www.optimumcomms.com/wp-content/uploads/2023/08/Astraveus.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-15 08:33:112025-04-15 08:33:11Astraveus Strengthens Leadership Team and Board
https://www.optimumcomms.com/wp-content/uploads/2023/10/Oxolife_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-09 12:59:372025-04-09 12:59:37Oxolife’s CEO Agnès Arbat receives prestigious EU Women Innovators Prize
https://www.optimumcomms.com/wp-content/uploads/2024/11/Infinitopes_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-09 10:33:472025-04-09 10:33:47Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer
https://www.optimumcomms.com/wp-content/uploads/2024/04/Xeltis_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-08 08:34:372025-04-08 09:54:08Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-02 09:10:232025-04-02 09:10:23Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies
https://www.optimumcomms.com/wp-content/uploads/2025/02/Domain_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-01 08:31:232025-04-01 08:31:23Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-03-28 09:53:252025-03-28 09:53:25Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
https://www.optimumcomms.com/wp-content/uploads/2025/03/Ellab_Logo_300x180px-80x80Web_Logos.jpg
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-03-27 11:34:422025-03-27 11:34:42Gergely Sved appointed CEO of Ellab
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-03-27 09:40:232025-03-27 09:40:23Poolbeg to Participate in Key Conferences in March and April 2025
https://www.optimumcomms.com/wp-content/uploads/2024/02/Alys_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-03-27 08:34:582025-03-27 08:34:58Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata
https://www.optimumcomms.com/wp-content/uploads/2025/03/Novo_Holdings23_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-03-26 11:00:262025-03-27 11:32:46Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
https://www.optimumcomms.com/wp-content/uploads/2024/03/Asgard_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-03-26 08:30:522025-03-28 10:13:44Asgard Therapeutics appoints immunology expert Shane Olwill as Chief Development Officer
https://www.optimumcomms.com/wp-content/uploads/2024/03/Heidelberg_Logo_300x180px-80x80Web_Logos-1.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2025-03-21 08:40:012025-03-25 14:18:52Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
https://www.optimumcomms.com/wp-content/uploads/2023/12/Poolbeg_Logo_300x180px-80x80Web_Logos.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2025-03-20 11:26:252025-03-25 14:09:50Poolbeg Pharma plc – POLB 001 Patent Granted in Korea
https://www.optimumcomms.com/wp-content/uploads/2024/09/iOnctura_Logo_300x180px-80x80Web_Logos.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2025-03-20 09:07:472025-03-25 14:20:45iOnctura commences randomized Phase II study in metastatic uveal melanoma
https://www.optimumcomms.com/wp-content/uploads/2025/02/Domain_Logo_300x180px-80x80Web_Logos.png
180
300
optimus
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
optimus2025-03-20 08:33:492025-03-25 14:04:34Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory DiseasesWe’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
